April 26-29, 2025
The Venetian Convention & Expo Center
Las Vegas, NV
Booth #2373
Connect with Caris Life Sciences at AUA 2025
Join Caris Life Sciences® at the upcoming American Urological Association (AUA) Annual Meeting in Las Vegas, NV. Visit our team at booth #2373 to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution.
Caris Assure
Caris Assure™ is a minimally invasive blood test that provides comprehensive molecular analysis of tumor biomarkers when tumor tissue is not feasible. The assay utilizes circulating Nucleic Acid Sequencing (cNAS), a novel approach to liquid biopsy that analyzes cell-free DNA and RNA from plasma, plus genomic DNA and messenger RNA from circulating white blood cells (WBCs) distinguish:
- Somatic tumor variants – This is the most critical information needed by a physician to make treatment decisions about targeted therapies. By distinguishing somatic (acquired) variants from incidental CH or incidental germline results, Caris Assure provides confidence in therapy decisions and avoidance of off-target drugs.
- Incidental CH – Clonal hematopoiesis (CH) mutations from aging white blood cells may cause false positive results for therapy selection. Caris Assure distinguishes CH from somatic tumor mutations to improve accuracy. Read the 2025 Study >
- Incidental germline† – Caris Assure analyzes genomic DNA from circulating white blood cells and can distinguish incidental germline mutations from somatic mutations. A germline mutation is present in even non-tumor cells and may not be a target for therapy.
Caris Assure has the potential to pick up more mutations, with a sensitivity of 93.8%* when compared to matched tissue collected within 30 days and using ≥5 ng of input material. Test results include genomic signatures, including microsatellite instability (MSI), blood tumor mutational burden (bTMB) and HLA genotyping, providing deep molecular insights to help inform therapy decisions.
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Profile
MI Profile™ comprehensive testing delivers whole exome sequencing (WES – DNA) and whole transcriptome sequencing (WTS – RNA) for 23,000+ genes, as well as protein analysis and AI-predictive algorithms. The test is designed to reveal a complete molecular blueprint that can guide more precise and individualized treatment decisions that help improve patient outcomes.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Complete Molecular Intelligence Report
The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent clinical trial opportunities.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.